newsfilter
← Latest News
GlobeNewswire·

Mydecine Innovations Group Announces MYCO-001 Seamless Phase 2/3 Smoking Cessation Clinical Trial

Dr. Matthew Johnson will lead research to look at the science and efficacy of MYCO-001 for the treatment of smoking cessation and nicotine dependence DENVER, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Mydecine Innovations Group™ (NEO:MYCO) (OTC:MYCOF) (FS